BlackRock Inc. Grows Holdings in Dr.Reddy’s Laboratories Ltd (RDY)

Share on StockTwits

BlackRock Inc. boosted its holdings in shares of Dr.Reddy’s Laboratories Ltd (NYSE:RDY) by 11.3% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,735,559 shares of the company’s stock after buying an additional 175,791 shares during the quarter. BlackRock Inc.’s holdings in Dr.Reddy’s Laboratories were worth $60,049,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Candriam Luxembourg S.C.A. acquired a new stake in Dr.Reddy’s Laboratories during the 3rd quarter worth approximately $623,000. Advisors Asset Management Inc. lifted its holdings in Dr.Reddy’s Laboratories by 29,814.7% during the 2nd quarter. Advisors Asset Management Inc. now owns 863,638 shares of the company’s stock worth $119,000 after buying an additional 860,751 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in Dr.Reddy’s Laboratories by 3,398.8% during the 2nd quarter. Renaissance Technologies LLC now owns 573,810 shares of the company’s stock worth $18,477,000 after buying an additional 557,410 shares in the last quarter. Northern Trust Corp lifted its holdings in Dr.Reddy’s Laboratories by 4.9% during the 2nd quarter. Northern Trust Corp now owns 380,284 shares of the company’s stock worth $12,245,000 after buying an additional 17,599 shares in the last quarter. Finally, Greenleaf Trust increased its position in shares of Dr.Reddy’s Laboratories by 24.9% in the 3rd quarter. Greenleaf Trust now owns 8,379 shares of the company’s stock valued at $290,000 after purchasing an additional 1,671 shares during the last quarter. Institutional investors own 11.39% of the company’s stock.

Shares of NYSE:RDY opened at $36.90 on Friday. Dr.Reddy’s Laboratories Ltd has a 52 week low of $28.13 and a 52 week high of $39.96. The company has a current ratio of 1.62, a quick ratio of 1.17 and a debt-to-equity ratio of 0.21. The company has a market capitalization of $6.15 billion, a price-to-earnings ratio of 36.57 and a beta of 0.15.

Dr.Reddy’s Laboratories (NYSE:RDY) last announced its quarterly earnings data on Friday, October 26th. The company reported $0.42 EPS for the quarter. Dr.Reddy’s Laboratories had a net margin of 10.62% and a return on equity of 13.14%. The company had revenue of $524.00 million for the quarter, compared to the consensus estimate of $522.22 million. On average, research analysts forecast that Dr.Reddy’s Laboratories Ltd will post 1.42 earnings per share for the current year.

A number of equities research analysts have commented on RDY shares. Zacks Investment Research raised shares of Dr.Reddy’s Laboratories from a “hold” rating to a “strong-buy” rating and set a $43.00 price objective on the stock in a research report on Monday, November 26th. ValuEngine downgraded shares of Dr.Reddy’s Laboratories from a “hold” rating to a “sell” rating in a research report on Thursday, October 4th.

ILLEGAL ACTIVITY WARNING: This piece of content was posted by Zolmax and is the sole property of of Zolmax. If you are viewing this piece of content on another publication, it was stolen and republished in violation of US & international copyright & trademark law. The original version of this piece of content can be viewed at https://zolmax.com/investing/blackrock-inc-grows-holdings-in-dr-reddys-laboratories-ltd-rdy/2820044.html.

Dr.Reddy’s Laboratories Profile

Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosage with therapeutic equivalence to branded formulations.

Featured Article: What Is An Exchange-Traded Fund (ETF)?

Want to see what other hedge funds are holding RDY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dr.Reddy’s Laboratories Ltd (NYSE:RDY).

Institutional Ownership by Quarter for Dr.Reddy`s Laboratories (NYSE:RDY)

Receive News & Ratings for Dr.Reddy's Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dr.Reddy's Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

ANNALY CAP MGMT/SH  Issues  Earnings Results
ANNALY CAP MGMT/SH Issues Earnings Results
ACCO Brands  Issues FY19 Earnings Guidance
ACCO Brands Issues FY19 Earnings Guidance
Insider Selling: DIGITAL RLTY TR/SH  Director Sells $44,052.00 in Stock
Insider Selling: DIGITAL RLTY TR/SH Director Sells $44,052.00 in Stock
Sun Life Financial  Releases Quarterly  Earnings Results, Beats Expectations By $0.32 EPS
Sun Life Financial Releases Quarterly Earnings Results, Beats Expectations By $0.32 EPS
The Coca-Cola  Posts  Earnings Results, Hits Estimates
The Coca-Cola Posts Earnings Results, Hits Estimates
Gossamer Bio Inc  Director Buys $115,200.00 in Stock
Gossamer Bio Inc Director Buys $115,200.00 in Stock


Leave a Reply

 
© 2006-2019 Zolmax.